MIRM · Mirum Pharmaceuticals, Inc.
$98.22
-2.38% last session
End-of-day data · close of 2026-09-11
Market cap
$7B
Enterprise value
$7B
Trailing P/E
—
Forward P/E
-290.2
Dividend yield
—
Beta
0.49
Avg volume
1M
Employees
0K
Daily Change %
-2.38%
5 Days Change
-2.58%
10 Days Change
0.25%
30 Days Change
0.07%
60 Days Change
-19.51%
Month to Day Change
-0.04%
Year to Day Change
24.45%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MIRM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-27
Latest call per bank · past 12 months
RBC Capital
Outperform$135
+34.2% vs priceJP Morgan
Overweight$125
+24.2% vs priceMorgan Stanley
Overweight$150
+49.1% vs priceCitigroup
Buy$145
+44.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Citizens | Reiterates | Market Outperform | $137 |
| 2026-08-06 | TD Cowen | Maintains | Buy | $145 → $140 |
| 2026-08-06 | RBC Capital | Maintains | Outperform | $148 → $135 |
| 2026-08-06 | Citizens | Maintains | Market Outperform | $146 → $137 |
| 2026-08-06 | HC Wainwright & Co. | Maintains | Buy | $185 → $140 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $142 → $148 |
| 2026-07-02 | JP Morgan | Maintains | Overweight | $115 → $125 |
| 2026-06-15 | Citizens | Maintains | Market Outperform | $140 → $146 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.5% below the 50-day MA ($107.31).
- Price vs 200-day MA: Trading 1.6% above the 200-day MA ($96.63).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.55) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($64.10) and high ($128.57).
MIRM Price Chart
Loading chart for MIRM…
Fundamentals
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.